BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20515481)

  • 1. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
    Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
    J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.
    Olofsson A; Willén H; Göransson M; Engström K; Meis-Kindblom JM; Stenman G; Kindblom LG; Aman P
    Int J Oncol; 2004 Nov; 25(5):1349-55. PubMed ID: 15492825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
    Bento C; Andersson MK; Aman P
    BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies.
    Thelin-Järnum S; Göransson M; Burguete AS; Olofsson A; Aman P
    Int J Cancer; 2002 Feb; 97(4):446-50. PubMed ID: 11802205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement for YAP1 signaling in myxoid liposarcoma.
    Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
    Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
    Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
    Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
    Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
    Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 15. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.
    Borjigin N; Ohno S; Wu W; Tanaka M; Suzuki R; Fujita K; Takanashi M; Oikawa K; Goto T; Motoi T; Kosaka T; Yamamoto K; Kuroda M
    Biochem Biophys Res Commun; 2012 Oct; 427(2):355-60. PubMed ID: 22995304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
    Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case.
    Zozumi M; Nakai M; Matsuda I; Hao H; Tsukamoto Y; Shiraishi Y; Nojima M; Yamamoto S; Hirota S
    Pathol Res Pract; 2013 Feb; 209(2):124-7. PubMed ID: 23276404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.
    Rodriguez R; Tornin J; Suarez C; Astudillo A; Rubio R; Yauk C; Williams A; Rosu-Myles M; Funes JM; Boshoff C; Menendez P
    Stem Cells; 2013 Oct; 31(10):2061-72. PubMed ID: 23836491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas.
    Oikawa K; Ishida T; Imamura T; Yoshida K; Takanashi M; Hattori H; Ishikawa A; Fujita K; Yamamoto K; Matsubayashi J; Kuroda M; Mukai K
    Am J Surg Pathol; 2006 Mar; 30(3):351-6. PubMed ID: 16538055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.
    Wu H; Xia L; Xu H
    Biochem Genet; 2022 Jun; 60(3):1095-1106. PubMed ID: 34792704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.